Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
DEMAC
Minneapolis, Minnesota, United States
- Ownership
- Private
- Employees
- ~35
- Development stage
- Other
01
Overview
DiaMedica Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel recombinant proteins to treat serious ischemic and vascular diseases. The company's lead candidate, DM199 (rinvecalinase alfa), is a recombinant form of human tissue kallikrein-1 (rhKLK1) designed to restore vascular health and improve blood flow in conditions such as acute ischemic stroke and preeclampsia. By leveraging the natural role of KLK1 in regulating blood pressure and inflammation, DiaMedica aims to provide disease-modifying therapies for patients with significant unmet medical needs. The company is currently advancing its lead program through late-stage clinical trials, including the ReMEDy2 Phase 2/3 trial for stroke.
- Therapeutic areas
- CardiovascularWomen's HealthGastroenterology
- Modalities
- Recombinant proteinSmall moleculeBiologic
- Industry
- Biotech
02
Partnerships
Health Canada (Regulatory clearance for Phase 2)
Beyond the preview
Go deeper on DEMAC.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DEMAC.